Training Hematology and Oncology Fellows in Clinical Research

培训血液学和肿瘤学研究员进行临床研究

• 批准号: 10675683
• 负责人: Claire F. Verschraegen
• 金额: $ 17.4万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10675683
• 关键词: Clinical Research; Hematology; Oncology; Training

PROJECT SUMMARY The objective of this Ohio State University postdoctoral clinical T32 training program entitled: “Training Hematology and Oncology Fellows in Clinical Research” is to provide a state of the art clinical research training experience, specifically for postdoctoral fellows in Hematology and Oncology with an M.D., D.O., or equivalent degree who have demonstrated a firm commitment to patient oriented cancer research. The overriding goal of this training program is to prepare Hematology and Oncology fellows in the OSU Divisions of Hematology and Medical Oncology for academic careers in patient oriented clinical and translational cancer investigation. Progress in cancer therapy and prevention requires strong collaborative efforts, and patient oriented physician investigators provide a critical link with physician-scientists and basic scientists toward this goal. The recent explosive growth of scientific discoveries and the increasing complexity of cancer clinical trials, particularly phase I/II studies of novel therapeutic agents and regimens, make it imperative that trainees in Hematology/Oncology acquire the proper training through appropriate mentoring, to prepare them for careers in clinical and translational investigation. This T32 program will prepare fellowship trainees for productive academic careers by providing an intellectually rigorous curriculum, strong mentoring and support from senior faculty, protected time for academic training during fellowship, “hands on” experience in developing and writing clinical studies and research papers, and ample opportunities to enhance their OSU experience with extramural programs and workshops sponsored by the NCI or other professional academic organizations such as ASCO and ASH. The participating members consist of the 2 Program Directors, Coordinating Committee members, Advisory Committee members, primary mentors, and contributing faculty, who were chosen based on their prior track record of successful mentoring and their demonstrated commitment to clinical and translational research. T32 fellows will commit for two years of training. The strengths of the OSUCCC, primarily in the fields of cancer prevention and experimental therapeutics, is the perfect environment to our planned success. Our T32 proposal is designed to foster and ensure the development of fellowship trainees, who we will train to assume academic clinical research positions as faculty members upon graduation. The T32 program is engineered to empower trainees to become independent clinical and translational investigators. Trainees will have mandatory an elective training in various settings, including the opportunity to obtain one or two master degrees; they will be required to create an investigator initiated clinical study and will start its implementation during training; they will be required to apply for funding for their own study through peer reviewed grant mechanisms; and they will be offered the opportunity to network nationally with the NCI and oncology professional organizations. OSUCCC is also deeply committed to training women and members of underrepresented racial and ethnic groups for academic careers as shown in continuous efforts to recruit and train female and underrepresented minority fellows.

项目总结 俄亥俄州立大学临床T32博士后培训项目的目标是： 临床研究血液学和肿瘤学研究员“是提供最先进的临床研究培训 经验，特别是血液学和肿瘤学博士后研究员，拥有医学博士、博士学位或同等学历 具有坚定致力于以病人为中心的癌症研究的学位。压倒一切的目标是 该培训计划是为俄亥俄州立大学血液学和肿瘤学分部的血液学和肿瘤学研究员做准备 面向患者的临床和转化性癌症研究的学术生涯的医学肿瘤学。 癌症治疗和预防的进步需要强有力的合作努力，以及以患者为中心的医生 研究人员为实现这一目标提供了与内科科学家和基础科学家的关键联系。最近的 科学发现的爆炸性增长和癌症临床试验的日益复杂，特别是阶段 I/II研究新的治疗药物和方案，使血液学/肿瘤学的受训人员成为当务之急 通过适当的指导获得适当的培训，为他们从事临床和翻译工作做好准备 调查。这项T32计划将通过提供以下方面的培训，帮助学员为富有成效的学术生涯做准备 智力严谨的课程，资深教职员工强有力的指导和支持，保护学术时间 团契期间的培训，在开发和撰写临床研究和研究论文方面的“实践”经验， 并有充足的机会通过赞助的校外项目和研讨会来增强他们在OSU的经验 由NCI或其他专业学术组织，如ASCO和ASH。参加会议的成员 由2名项目主任、协调委员会成员、咨询委员会成员、主要成员组成 导师和特约教员，他们是根据他们以前成功指导的记录来选择的 以及他们对临床和转译研究的承诺。T32研究员将承诺两年 训练有素。OSUCCC的优势，主要是在癌症预防和实验领域 治疗，是我们取得计划成功的完美环境。我们的T32提案旨在促进和 确保奖学金学员的发展，我们将对他们进行培训，以承担学术临床研究职位 作为毕业时的教职员工。T32计划旨在帮助学员成为 独立的临床和翻译研究人员。学员将接受各种形式的强制性选修培训 设置，包括获得一个或两个硕士学位的机会；它们将被要求创建 研究人员发起了临床研究，并将在培训期间开始实施；他们将被要求申请 通过同行评审的资助机制为他们自己的研究提供资金；他们将获得机会 在全国范围内与NCI和肿瘤学专业组织建立网络。OSUCCC也深深地致力于 培训妇女和代表不足的种族和民族群体的成员从事学术职业 继续努力招聘和培训女性和代表性不足的少数群体研究员。

项目成果

Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.

• DOI: 10.1177/17588359231217976
• 发表时间: 2023
• 期刊: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
• 影响因子: 4.9
• 作者: Williams, Nicole O.;Quiroga, Dionisia;Johnson, Courtney;Brufsky, Adam;Chambers, Mara;Bhattacharya, Saveri;Patterson, Maria;Sardesai, Sagar D.;Stover, Daniel;Lustberg, Maryam;Noonan, Anne M.;Cherian, Mathew;Bystry, Darlene M.;Hill, Kasey L.;Chen, Min;Phelps, Mitch A.;Grever, Michael;Stephens, Julie A.;Ramaswamy, Bhuvaneswari;Carson III, William E.;Wesolowski, Robert
• 通讯作者: Wesolowski, Robert

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.

• DOI: 10.1038/s41523-021-00349-y
• 发表时间: 2021-11-11
• 期刊: NPJ breast cancer
• 影响因子: 5.9
• 作者: Metzger-Filho O;Collier K;Asad S;Ansell PJ;Watson M;Bae J;Cherian M;O'Shaughnessy J;Untch M;Rugo HS;Huober JB;Golshan M;Sikov WM;von Minckwitz G;Rastogi P;Li L;Cheng L;Maag D;Wolmark N;Denkert C;Symmans WF;Geyer CE Jr;Loibl S;Stover DG
• 通讯作者: Stover DG

Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.

• DOI: 10.1002/cam4.4587
• 发表时间: 2022-04
• 期刊: Cancer medicine
• 影响因子: 4
• 作者: Yang Y;Mori SV;Li M;Hinkley M;Parikh AB;Collier KA;Miah A;Yin M
• 通讯作者: Yin M

Triple-negative breast cancer: promising prognostic biomarkers currently in development.

• DOI: 10.1080/14737140.2021.1840984
• 发表时间: 2021-03
• 期刊: Expert review of anticancer therapy
• 影响因子: 3.3
• 作者: Sukumar J;Gast K;Quiroga D;Lustberg M;Williams N
• 通讯作者: Williams N

Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.

• DOI: 10.1007/s10549-021-06368-4
• 发表时间: 2021-11
• 期刊: Breast cancer research and treatment
• 影响因子: 3.8
• 作者: Sukumar JS;Quiroga D;Kassem M;Grimm M;Shinde NV;Appiah L;Palettas M;Stephens J;Gatti-Mays ME;Pariser A;Cherian M;Stover DG;Williams N;Van Deusen J;Wesolowski R;Lustberg M;Ramaswamy B;Sardesai S
• 通讯作者: Sardesai S